/
EBS
$4.49-$0.06 (-1.32%)prev close
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$233.3M
51M shares
52-week range
$4.36 – $14.06
1% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NYSE
CS
Change$-55.37
Emergent Biosolutions, Inc.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.
www.emergentbiosolutions.com- Employees
- 900
- IPO / List date
- Nov 15, 2006
- HQ
- GAITHERSBURG, MD
Held by traders on TradeandTell
No one on the platform currently holds EBS.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 656,047 | $5.4M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded EBS yet.
